



Hans-Dieter Volk is Director of the Institute of Medical Immunology and the Berlin-Brandenburg Center for Regenerative Therapies. Several biotech enterprises has been established from technology platforms developed at his Institute (Probiogen AG, Jerini AG, Cellserve GmbH). Several biomarker assays developed at the institute were commercialized.

Prof Volk's research bridges the gap between basic research and clinical research. His work focuses on the implementation of new approaches in the diagnosis and treatment of immunological diseases. His research interests include transplantation immunology, immunology of viral infections (CMV, EBV), immunology of intensive care patients, immuno-cell therapy (adoptive transfer of T cells and mesenchymal stem cells), immunodermatology and protein-protein interactions. The research at the Inst.Med. Immunology focusses at biomarker development for guiding immunomodulatory therapies in transplantation, intensive care, and psoriasis as well as for testing safety(efficacy of novel drugs (phase I/II trials).

The research of the BCRT comprises of three multidisciplinary platforms: (a) basic science (genomics, proteomics, bioinformatics, cell biology, immune methods); (b) Bioengineering (biomaterial development, scaffold engineering, biointerface engineering, cellular engineering and drug delivery systems); and (c) translational technology (cell and factor delivery, applied cell biology, bioreactors and preclinical testing) working on topics related to four medically oriented fields namely the immune system, cardio-vascular system, nervous system and musculoskeletal system. Key projects are related to cell therapy, bio-materials and biomarkers

<http://www.termis.org/eu2010/keynote.php>